Sinapsos Podcast | Oncology

E56   |  10 min   |   Latest   |  Publication Link

• Podcast based on: Aljabali, A.A.A.; Obeid, M.A.; Alqudah, A.; Hamzat, Y.; Alqudah, A.; Alzoubi, L.; Gammoh, O.; Qnais, E.; Mishra, V.; Mishra, Y.; Hatahet, T.; El-Tanani, M. CAR T-Cell Therapy in Hematological Malignancies: Mechanisms, Innovations, and Challenges. Cancers 2026, 18, 3254. https://doi.org/10.3390/cancers18203254
  Type: Review  |  Publication date: 09 October 2026
  
  
• Summary: Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary immunotherapy that engineers a patient’s own immune T cells to specifically target and destroy malignant cells in hematological malignancies. This approach has transformed the treatment of relapsed acute lymphoblastic leukemia, lymphomas, and myelomas, leading to seven products approved by the U.S. Food and Drug Administration (FDA) that offer curative potential for patients who previously had no remaining options. However, the therapy is not without significant challenges. Severe inflammatory toxicities, cancer relapse due to the loss of target antigens, and the high costs of individualized manufacturing limit its broader use. This review explores the biological mechanisms driving CAR T-cell success and failure, details the current landscape of approved and investigational therapies, and highlights emerging innovations. Strategies such as targeting multiple antigens simultaneously, engineering next-generation CARs, and developing off-the-shelf products are critical next steps to improve safety, overcome resistance, and make this life-saving therapy accessible to more patients.
  
  
• Keywords: chimeric antigen receptor (CAR) T-cell therapy; hematological malignancies; immune checkpoint inhibitors; multiplexed antigen targeting; next-generation immunotherapy

License and disclaimer:
Original article © 2026 by the authors. Licensed under the Creative Commons Attribution 4.0 (CC BY 4.0) license (https://creativecommons.org/licenses/by/4.0/). This episode is an AI-generated audio adaptation of the article: the script and the voices are synthetic, changes were made, and the adaptation is not endorsed by the authors, the journal, or the publisher. It may contain errors or omissions, so consult the original publication before relying on any detail. It is for educational purposes only and is not medical advice. The creators accept no liability for any use of this content.